1. EdwardsMS (2006) Issues of antimicrobial resistance in group B streptococcus in the era of intrapartum antibiotic prophylaxis. Semin Pediatr Infect Dis 17: 149–152.
2. HeathPT, SchuchatA (2007) Perinatal group B streptococcal disease. Best Pract Res Clin Obstet Gynaecol 21: 411–424.
3. ThigpenMC, WhitneyCG, MessonnierNE, ZellER, LynfieldR, et al. (2011) Bacterial meningitis in the United States, 1998–2007. N Engl J Med 364: 2016–2025.
4. FerrieriP, ClearyPP, SeedsAE (1977) Epidemiology of group-B streptococcal carriage in pregnant women and newborn infants. J Med Microbiol 10: 103–114.
5. GalaskRP, VarnerMW, PetzoldCR, WilburSL (1984) Bacterial attachment to the chorioamniotic membranes. Am J Obstet Gynecol 148: 915–928.
6. PharesCR, LynfieldR, FarleyMM, Mohle-BoetaniJ, HarrisonLH, et al. (2008) Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA 299: 2056–2065.
7. BedfordH, de LouvoisJ, HalketS, PeckhamC, HurleyR, et al. (2001) Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 323: 533–536.
8. EdmondKM, KortsalioudakiC, ScottS, SchragSJ, ZaidiAK, et al. (2012) Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 379: 547–556.
9. BaltimoreRS (2007) Consequences of prophylaxis for group B streptococcal infections of the neonate. Semin Perinatol 31: 33–38.
10. CastorML, WhitneyCG, Como-SabettiK, FacklamRR, FerrieriP, et al. (2008) Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008: 727505.
11. SchuchatA (1998) Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 11: 497–513.
12. EdwardsMS, BakerCJ (2005) Group B streptococcal infections in elderly adults. Clin Infect Dis 41: 839–847.
13. SkoffTH, FarleyMM, PetitS, CraigAS, SchaffnerW, et al. (2009) Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990–2007. Clin Infect Dis 49: 85–92.
14. RubensCE, WesselsMR, HeggenLM, KasperDL (1987) Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A 84: 7208–7212.
15. WesselsMR, RubensCE, BenediVJ, KasperDL (1989) Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A 86: 8983–8987.
16. MarquesMB, KasperDL, PangburnMK, WesselsMR (1992) Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun 60: 3986–3993.
17. TakahashiS, AoyagiY, AddersonEE, OkuwakiY, BohnsackJF (1999) Capsular sialic acid limits C5a production on type III group B streptococci. Infect Immun 67: 1866–1870.
18. CrockerPR, PaulsonJC, VarkiA (2007) Siglecs and their roles in the immune system. Nat Rev Immunol 7: 255–266.
19. VarkiA (2007) Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature 446: 1023–1029.
20. CaoH, CrockerPR (2011) Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology 132: 18–26.
21. PillaiS, NetravaliIA, CariappaA, MattooH (2012) Siglecs and immune regulation. Annu Rev Immunol 30: 357–392.
22. VarkiA, AngataT (2006) Siglecs–the major subfamily of I-type lectins. Glycobiology 16: 1R–27R.
23. PaulSP, TaylorLS, StansburyEK, McVicarDW (2000) Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 96: 483–490.
24. UlyanovaT, BlasioliJ, Woodford-ThomasTA, ThomasML (1999) The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol 29: 3440–3449.
25. UlyanovaT, ShahDD, ThomasML (2001) Molecular cloning of MIS, a myeloid inhibitory siglec, that binds protein-tyrosine phosphatases SHP-1 and SHP-2. J Biol Chem 276: 14451–14458.
26. VarkiA (2011) Since there are PAMPs and DAMPs, there must be SAMPs? Glycan “self-associated molecular patterns” dampen innate immunity, but pathogens can mimic them. Glycobiology 21: 1121–1124.
27. CarlinAF, LewisAL, VarkiA, NizetV (2007) Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes. J Bacteriol 189: 1231–1237.
28. CarlinAF, UchiyamaS, ChangYC, LewisAL, NizetV, et al. (2009) Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 113: 3333–3336.
29. ZhangJQ, BiedermannB, NitschkeL, CrockerPR (2004) The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol 34: 1175–1184.
30. BoydCR, OrrSJ, SpenceS, BurrowsJF, ElliottJ, et al. (2009) Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production. J Immunol 183: 7703–7709.
31. McMillanSJ, SharmaRS, McKenzieEJ, RichardsHE, ZhangJ, et al. (2013) Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b beta2-integrin-dependent signalling. Blood 121: 2084–2094.
32. RedelinghuysP, AntonopoulosA, LiuY, Campanero-RhodesMA, McKenzieE, et al. (2011) Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E. J Biol Chem 286: 34522–34532.
33. GergelyJ, PechtI, SarmayG (1999) Immunoreceptor tyrosine-based inhibition motif-bearing receptors regulate the immunoreceptor tyrosine-based activation motif-induced activation of immune competent cells. Immunol Lett 68: 3–15.
34. ZhangJ, SomaniAK, SiminovitchKA (2000) Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol 12: 361–378.
35. TaylorLS, PaulSP, McVicarDW (2000) Paired inhibitory and activating receptor signals. Rev Immunogenet 2: 204–219.
36. ChangYC, UchiyamaS, VarkiA, NizetV (2012) Leukocyte inflammatory responses provoked by pneumococcal sialidase. MBio 3: e00220–11.
37. AndoM, TuW, NishijimaK, IijimaS (2008) Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem Biophys Res Commun 369: 878–883.
38. ChenGY, ChenX, KingS, CavassaniKA, ChengJ, et al. (2011) Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol 29: 428–435.
39. ShigeokaAO, RoteNS, SantosJI, HillHR (1983) Assessment of the virulence factors of group B streptococci: correlation with sialic acid content. The Journal of infectious diseases 147: 857–863.
40. WesselsMR, HaftRF, HeggenLM, RubensCE (1992) Identification of a genetic locus essential for capsule sialylation in type III group B streptococci. Infection and immunity 60: 392–400.
41. RivestS (2009) Regulation of innate immune responses in the brain. Nat Rev Immunol 9: 429–439.
42. MarianiMM, KielianT (2009) Microglia in infectious diseases of the central nervous system. J Neuroimmune Pharmacol 4: 448–461.
43. AbbottNJ, PatabendigeAA, DolmanDE, YusofSR, BegleyDJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37: 13–25.
44. GuptaN, ScharenbergAM, BurshtynDN, WagtmannN, LioubinMN, et al. (1997) Negative signaling pathways of the killer cell inhibitory receptor and Fc gamma RIIb1 require distinct phosphatases. J Exp Med 186: 473–478.
45. MaedaA, KurosakiM, OnoM, TakaiT, KurosakiT (1998) Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal. J Exp Med 187: 1355–1360.
46. OnoM, BollandS, TempstP, RavetchJV (1996) Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 383: 263–266.
47. LajauniasF, DayerJM, ChizzoliniC (2005) Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol 35: 243–251.
48. OhtaM, IshidaA, TodaM, AkitaK, InoueM, et al. (2010) Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9. Biochem Biophys Res Commun 402: 663–669.
49. ClynesR, MaizesJS, GuinamardR, OnoM, TakaiT, et al. (1999) Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 189: 179–185.
50. NadlerMJ, McLeanPA, NeelBG, WortisHH (1997) B cell antigen receptor-evoked calcium influx is enhanced in CD22-deficient B cell lines. J Immunol 159: 4233–4243.
51. O'KeefeTL, WilliamsGT, DaviesSL, NeubergerMS (1996) Hyperresponsive B cells in CD22-deficient mice. Science 274: 798–801.
52. YuasaT, KuboS, YoshinoT, UjikeA, MatsumuraK, et al. (1999) Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med 189: 187–194.
53. ZhangM, AngataT, ChoJY, MillerM, BroideDH, et al. (2007) Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 109: 4280–4287.
54. CrockerPR, McMillanSJ, RichardsHE (2012) CD33-related siglecs as potential modulators of inflammatory responses. Ann N Y Acad Sci 1253: 102–111.
55. StrleK, ZhouJH, ShenWH, BroussardSR, JohnsonRW, et al. (2001) Interleukin-10 in the brain. Crit Rev Immunol 21: 427–449.
56. MalipieroU, KoedelU, PfisterHW, LeveenP, BurkiK, et al. (2006) TGFbeta receptor II gene deletion in leucocytes prevents cerebral vasculitis in bacterial meningitis. Brain 129: 2404–2415.
57. BanerjeeS, BhatMA (2007) Neuron-glial interactions in blood-brain barrier formation. Annu Rev Neurosci 30: 235–258.
58. WangY, NeumannH (2010) Alleviation of neurotoxicity by microglial human Siglec-11. J Neurosci 30: 3482–3488.
59. LewisAL, NizetV, VarkiA (2004) Discovery and characterization of sialic acid O-acetylation in group B Streptococcus. Proc Natl Acad Sci USA 101: 11123–11128.
60. AngataT, VarkiA (2000) Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways. J Biol Chem 275: 22127–22135.
61. MoussaudS, DraheimHJ (2010) A new method to isolate microglia from adult mice and culture them for an extended period of time. J Neurosci Methods 187: 243–253.
62. DoranKS, EngelsonEJ, KhosraviA, MaiseyHC, FedtkeI, et al. (2005) Blood-brain barrier invasion by group B Streptococcus depends upon proper cell-surface anchoring of lipoteichoic acid. J Clin Invest 115: 2499–2507.